Stock ADMS ADAMAS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Analyst Reco. Adamas Pharmaceuticals, Inc.

Equities

ADMS

US00548A1060

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Northland Downgrades Adamas Pharmaceuticals to Market Perform From Outperform; Price Target is $8.50
MT
ADAMAS PHARMACEUTICALS : SVB Leerink Downgrades Adamas Pharmaceuticals to Market perform From Outperform, Adjusts Price Target to $8 From $6
MT
ADAMAS PHARMACEUTICALS : JMP Securities Downgrades Adamas Pharmaceuticals to Market Perform from Market Outperform
MT
ADAMAS PHARMACEUTICALS : Piper Sandler Downgrades Adamas Pharmaceuticals to Neutral from Overweight, Adjusts Price Target to $8 from $7
MT
ADAMAS PHARMACEUTICALS : HC Wainwright Downgrades Adamas Pharmaceuticals to Neutral From Buy, Trims Price Target to $9.10 From $10
MT
ADAMAS PHARMACEUTICALS : William Blair Downgrades Adamas Pharmaceuticals to Market Perform From Outperform
MT
ADAMAS PHARMACEUTICALS : HC Wainwright Adjusts Price Target on Adamas Pharmaceuticals to $10 From $12, Maintains Buy Rating
MT
ADAMAS PHARMACEUTICALS : HC Wainwright Adjusts Price Target on Adamas Pharmaceuticals to $12 From $10, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ADMS Stock
  4. News Adamas Pharmaceuticals, Inc.
  5. Analyst Reco.